Expertise in
18
conditions

Dr. Victor Aquino

Hematology | Oncology
Children's Medical Center/Children's Health
1935 Medical District Dr, 
Dallas, TX 
32 Years of Experience
Expertise in
18
conditions
Children's Medical Center/Children's Health
1935 Medical District Dr, 
Dallas, TX 

Overview

Victor Aquino is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. He has been practicing medicine for over 32 years.

Dr. Aquino is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Severe Combined Immunodeficiency (SCID), X-Linked Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome, Graft Versus Host Disease (GvHD), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 42 peer reviewed articles and participating in 14 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Cook Children's Health Plan
  • MANAGED MEDICAID PLAN
FirstCare
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Magnolia Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

Children's Medical Center/Children's Health
1935 Medical District Dr, Dallas, TX 75235
Other Locations
University of Texas Southwestern Medical Center
5323 Harry Hines Blvd, Dallas, TX 75390

Additional Areas of Focus

Dr. Aquino has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: February 25, 2026
Intervention Type: Drug, Other
Study Drug: Omidubicel
Study Phase: Phase 3
A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
Enrollment Status: Active_not_recruiting
Publish Date: February 17, 2026
Intervention Type: Drug, Device
Study Drug: Busulfan
Study Phase: Phase 2
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: January 05, 2026
Intervention Type: Other
Study Phase: Not Applicable
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701
Enrollment Status: Active_not_recruiting
Publish Date: May 11, 2025
Intervention Type: Biological
Study Drug: Virus Specific T-cell infusion
Study Phase: Phase 1/Phase 2
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Enrollment Status: Completed
Publish Date: October 16, 2024
Intervention Type: Drug, Other
Study Phase: Phase 3
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Enrollment Status: Terminated
Publish Date: September 29, 2023
Intervention Type: Biological, Drug
Study Drugs: Rivogenlecleucel, Rimiducid
Study Phase: Phase 1/Phase 2
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Enrollment Status: Unknown
Publish Date: February 08, 2023
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug
Study Drugs: BPX-501 T Cells, Rimiducid
Study Phase: Phase 1/Phase 2
A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Enrollment Status: Completed
Publish Date: March 17, 2022
Intervention Type: Drug
Study Phase: Phase 3
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Enrollment Status: No_longer_available
Publish Date: March 14, 2022
Intervention Type: Drug
View 9 Less Clinical Trials

42 Total Publications

Factors Associated With Pre-donation Health-related Quality-of-Life Among Pediatric Sibling Hematopoietic Cell Donors: A DonorKids QL Study.
Factors Associated With Pre-donation Health-related Quality-of-Life Among Pediatric Sibling Hematopoietic Cell Donors: A DonorKids QL Study.
Journal: Transplantation and cellular therapy
Published: December 11, 2025
Similar Doctors
Expertise in
39
conditions
Dr. Farrukh Awan
Hematology | Oncology
Expertise in
39
conditions
Dr. Farrukh Awan
Hematology | Oncology
Referral may be required

UT Southwestern-Bill And Rita Clements Advanced Medical Imaging Center

2201 Inwood Rd, 
Dallas, TX 
 (0.6 miles away)
214-645-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Farrukh Awan is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. Dr. Awan is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
10
conditions
Dr. Naomi Winick
Hematology | Oncology
Expertise in
10
conditions
Dr. Naomi Winick
Hematology | Oncology
Referral may be required

Children's Medical Center/Children's Health

1935 Medical District Dr, 
Dallas, TX 
 (0.2 miles away)
214-648-3896
Languages Spoken:
English
See accepted insurances

Naomi Winick is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. Dr. Winick is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Infantile Neutropenia, Febrile Neutropenia, and Bone Marrow Transplant.

Expertise in
11
conditions
Dr. Alecia Nero
Hematology | Oncology
Expertise in
11
conditions
Dr. Alecia Nero
Hematology | Oncology
Referral may be required

University Of Texas Southwestern Medical Center

5323 Harry Hines Blvd, 
Dallas, TX 
 (0.1 miles away)
214-648-4180
Languages Spoken:
English
See accepted insurances

Alecia Nero is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. Dr. Nero is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Victor Aquino

How do I make an appointment with Dr. Victor Aquino?

You can book an appointment with Dr. Victor Aquino by calling their office at 214-456-2382. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Victor Aquino a top-rated expert for Severe Combined Immunodeficiency (SCID)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Victor Aquino is classified as an Elite expert for Severe Combined Immunodeficiency (SCID), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Victor Aquino specialize in?

While Dr. Victor Aquino is a Hematology, they have specific expertise in Severe Combined Immunodeficiency (SCID), X-Linked Severe Combined Immunodeficiency, and Wiskott-Aldrich Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Victor Aquino participate in research or clinical trials?

Yes. Dr. Victor Aquino has published 42 articles and abstracts on conditions like Severe Combined Immunodeficiency (SCID). You can view a list of Dr. Victor Aquino's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Victor Aquino accept my insurance?

Dr. Victor Aquino accepts most major insurance plans, including Baylor Scott & White Health and Cook Children's Health Plan. We recommend calling the office directly at 214-456-2382 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Aquino's expertise for a condition
ConditionClose
View All 15 Advanced Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile